BACKGROUND: Asthma medication ratio (AMR) ≥ 0.5 has been shown to predict asthma exacerbations. This study explores the impact of increasing or decreasing inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) use over a 7-year period on achieving an AMR of ≥ 0.5.
A sthma is a chronic inflammatory disorder of the airways characterized by episodic and reversible airflow obstruction, airway hyper-responsiveness, and underlying inflammation. 1 Common asthma symptoms include wheezing, coughing, and shortness of breath. The majority of asthmatic patients can expect optimal symptom control with correct treatment and avoidance of exposure to environmental allergens and irritants that are known to exacerbate asthma. 2 In 2010, an estimated 18.8 million adults and 7 million children in the United States had current asthma. 2 In 2009, there were 2.1 million emergency department visits, 479,300 hospitalizations, and approximately 10.6 million physician office visits for asthma. 2, 3 Previous research has shown that the increased use of inhaled corticosteroids (ICSs) is associated with reduced risk of future asthma exacerbations and mortality. It has been estimated that regular use of ICSs could reduce asthma hospitalizations by as much as 80%, and that the risk of death from asthma decreases by 21% for each additional ICS canister used. [4] [5] [6] [7] In addition, the overuse of albuterol has been observed to be associated with an increase in the risk of future asthma exacerbations. 8, 9 In 2011, the National Committee of Quality Assurance endorsed a Healthcare Effectiveness Data and Information Set (HEDIS) measure to assess asthma treatment and future asthma exacerbation risk. 10 This HEDIS measure includes several parts, one being controller adherence, measured using pharmacy claims data, that assesses appropriate treatment. Another measure is the asthma medication ratio (AMR), which assesses future asthma risk. The AMR, which is a ratio of controller use over total asthma medications, has been shown to predict future asthma exacerbations using an AMR threshold of ≥ 0.5. 11, 12 • The asthma medication ratio (AMR) is currently being used as a Healthcare Effectiveness Data and Information Set asthma quality measure endorsed by the National Committee for Quality Assurance.
• The AMR value of ≥ 0.5 has been associated with lower risk of subsequent asthma-related exacerbations. Low adherence rates to inhaled corticosteroid (ICS) use may be related to poorer asthma control. Use of ICS/long-acting beta-agonist (LABA) as a fixed-dose combination to ICS alone has not been associated with changes in AMR over time.
What is already known about this subject
• The data from this analysis support the finding that increased use of an ICS/LABA combination in asthma was associated with a greater likelihood of achieving an AMR of ≥ 0.5.
• Increasing the use of ICS by improving adherence and/or reducing the need for rescue albuterol can increase the AMR. Figure 1 .
What this study adds

Study Exposures and Outcomes
The controller-to-total AMR is calculated as the ratio of 30-day supply/canisters of controller medications used during the measurement year divided by the sum of 30-day supply/canisters of controller medications plus the canisters of inhaled short-acting beta-agonists used during the measurement year.
Controller medications include leukotriene receptor antagonists (LTRAs), ICSs, ICS plus LABAs fixed-dose combination inhalers, and methyl xanthenes. The ratio of ≥ 0.5 for the AMR is recommended as the cutoff in assessing asthma risk in a population and is associated with a reduction in the risk of asthma-related exacerbation in the following year. 11, 12 In order to assess the effect of changing ICS use over time on the AMR, a modified version of the AMR (mAMR), which used only ICSs in the denominator and numerator, was used in this analysis. Excluding LTRA use in the calculation of the AMR allowed for a more robust analysis of the effect of ICS use, considering LTRAs are used to treat allergic rhinitis, which could confound the association of ICS use and AMR. Values for the mAMR ranged from 0 (no ICS + albuterol) to 1 (ICS + no albuterol). The objectives of this study were to (a) assess the impact of increasing use of ICS/LABA on changes in a modified AMR (mAMR) and (b) examine asthma risk over time as measured by an mAMR over a 7-year period, adjusting for differences in baseline characteristics.
■■ Methods Study Population and Design
The study was conducted using data from Sharp HealthCare, a not-for-profit, integrated health care system based in San Diego comprising 4 acute-care hospitals, 3 specialty hospitals, 3 skilled nursing facilities, 2 affiliated medical groups, 2,600 physicians, and more than 16,000 employees. As a part of Sharp HealthCare, Sharp Rees-Stealy is San Diego's first multispecialty medical group practice, with 450 physicians, 2,000 staff members, and 21 medical center locations throughout San Diego County. Sharp Rees-Stealy cares for nearly 200,000 patients, primarily through managed care risk contracts.
This was a retrospective observational study using pharmacy and medical administrative claims data from Sharp HealthCare. The study population included adult and pediatric asthma subjects aged ≥ 4 years who were identified in the database from 
Study Design
A ratio of ICS/LABA to total ICS use was used to assess changing ICS/LABA and ICS use over time. This ratio was determined annually and semiannually as the number of ICS/ LABA canisters dispensed divided by the sum of ICS/LABA and ICS monotherapy dispensed. In addition, the annual and semiannual albuterol canister use was also determined over the 7-year period.
After calculating the ICS/LABA to the total ICS use ratio and mAMR, we determined the effect of changes in ICS/LABA use over time on the likelihood of achieving an mAMR ratio of ≥ 0.5, taking into account baseline differences.
Statistical Analysis
Demographic characteristics and baseline medical conditions were described for the identified asthma cohort using standard summary statistics (means and percentages). To ensure accuracy, the data were reviewed for internal consistency and checked for influential outliers. Generalized linear mixed models (GLMMs) were used to generate predicted mean mAMR, mean ratio of ICS/LABA use, and mean numbers of albuterol canisters over the annual and semiannual periods, adjusting for baseline covariates. The covariates used for the analyses were patient demographic characteristics, overall asthma burden, and resource use in the pre-index period.
Random effects within the patients and the correlations between different time intervals were also handled using GLMMs. The GLMMs were used to assess the relationship between increasing ICS/LABA to ICS market share ratio and the likelihood of achieving an mAMR of > 0.5. Adjusted odds ratios (ODs) and corresponding 95% confidence intervals (CIs) were generated, adjusting for covariates and time. Models were run for both the annual and semiannual assessments of ICS/LABA to total ICS ratio and mAMR. All analysis was conducted using SAS software package 9.2 (SAS Institute Inc., Cary, NC). 13 
■■ Results
A total of 23,230 subjects were eligible for inclusion into the analysis, with 11,970 of these subjects with asthma and no COPD using at least 1 asthma controller or albuterol during the 7-year period. Attrition of the population when all the inclusion and exclusion criteria were applied to this population is shown in Table 1 . A final population of 990 patients met all the inclusion criteria. Mean age of the population was 34.7 years (standard deviation [SD] ± 18.20) with 61.7% female. In addition, mean use of albuterol was 0.53 (SD ± 1.85), and mean use of oral corticosteroids was 0.25 (SD ± 0.83) in the pre-index period. Other baseline characteristics for these patients are presented in Table 2 .
Annual and semiannual adjusted mean mAMR, ICS/LABA, and albuterol use to total ICS use ratio over a 7-year period are plotted in Figure 2 . Overall, trends over time show that mean annual and semiannual mAMR increased over the 7 years, while the corresponding mean albuterol use decreased over that same time period. The regression analysis predicting the likelihood of achieving an mAMR of ≥ 0.5 showed that a 10% increase in annual or semiannual ICS/LABA to total ICS use ratio was associated with a 9% increase (adjusted OR = 1.09, 95% CI = 1.06-1.12) and an 8% increase (OR = 1.08, 95% CI = 1.05-1.11) in the likelihood of achieving an mAMR of ≥ 0.5, respectively (Table 3 ). In addition, a 50% increase in ICS/LABA use resulted in a 53% and a 48% increase in the likelihood of achieving an mAMR of ≥ 0.5 for the annual and semiannual assessments, respectively. This suggests that an increase in the use of ICS/LABA over time was associated with lower asthma risk in this population of asthma patients. 
C. Adjusted Mean Albuterol Use a Generalized linear mixed model adjusting for index year, age, sex, number of albuterol canisters dispensed, total number of oral corticosteroids dispensed, number of unique drug classes dispensed, total number of medications dispensed, Charlson Comorbidity Index, total number of unique 3-digit diagnoses codes, total number of asthma-related hospital stays, total number of asthma-related office visits, and total number of asthma-related emergency department visits. ICS = inhaled corticosteroid; LABA = long-acting beta-agonist; mAMR = modified asthma medication ratio.
Number of Periods
■■ Discussion
This analysis highlights the association of increasing use of ICS/LABA on a new HEDIS quality measure, AMR. The AMR is a measure of asthma exacerbation risk, and this study shows an association of increasing use of ICS/LABA on reducing this risk. This is the first study that has looked at the ratio of ICS/ LABA to total ICS use on asthma exacerbation risk. However, several observational studies have shown the benefits of increasing ICS use on asthma exacerbation risk and mortality. [4] [5] [6] 14 Stern et al. (2006) assessed the effect of decreasing use of ICS on future asthma exacerbations. 6 The authors concluded that every 25% decrease in ICS use over a year was associated with a 10% increase in the risk of asthma-related severe exacerbations. 6 Delea et al. (2008) were able to show that increasing ICS/LABA use had a similar risk reduction on asthma exacerbation. 15 In addition, Suissa et al. (2000) were able to link increasing ICS use with asthma-related mortality, showing that every canister increase in ICS use in a year was associated with a 21% reduction in asthma-related mortality. 4 The use of high levels of albuterol has been associated with an increased risk of asthma-related exacerbations. Schatz et al. (2010) , using data from Kaiser Permanente Southern California, associated high levels of albuterol use with poor asthma outcomes. 9 They concluded that asthma patients receiving more than 4 canisters of albuterol in a year were 24% more likely to have asthma-related hospital care in the following year. Stanford et al. (2012) showed, after controlling for the use of ICS, that every canister increase in albuterol in a year was associated with an 11% increase in the risk of an asthmarelated exacerbation in the following year. 8 The AMR value can be increased several ways: (a) increasing adherence to controllers; (b) decreasing the use of albuterol; and (c) a combination of both. So the effect of increasing ICS/LABA use on a higher likelihood of AMR being ≥ 0.5 is plausible, considering that observational studies have shown that patients on ICS/LABA as fixed-dosed inhalers tend to refill their controllers more often compared with those on ICS monotherapy. [16] [17] [18] In addition, the use of ICS/LABA has also been shown to reduce the need for albuterol compared with ICS alone. 19, 20 So these observed outcomes together could improve the AMR value in a population of asthmatics.
Whether this effect of ICS/LABA on increasing AMR ultimately reduces future asthma exacerbations remains to be observed. However, a recent network meta-analysis of randomized clinical studies assessing the effect of ICS/LABA in asthma observed a significant 49% reduction in severe exacerbations compared with low-dose ICS. 21 This finding is supported by several observational studies. 19, 20, 22, 23 Limitations There are several limitations of the present analysis that should be considered when interpreting this data. Several variables that could affect the observed outcomes were not fully captured in the database, such as lung function information, clinical measures of asthma control, physician samples used by patients, socioeconomic factors, education, and patient employment status. In addition, direct measure of asthma severity was not captured in this dataset.
The methodology and statistical plan for this study that included proxy measures of disease burden and asthma control was used to mitigate the effect of prescribing bias; however, residual confounding may still exist due to the observational nature of this study. In addition, the generalizability outside of this health plan may be limited. However, the use of one health plan allowed for less heterogeneity than would be observed if multiple health plans were used in the analysis. Furthermore, formulary status of medications are not usually known when multiplan datasets are employed; we used only one health plan so the formulary status of ICS/LABA and ICS monotherapy was known and was considered to be equal during the time period of the study.
■■ Conclusions
The results of this study suggest that the mean mAMR increased over a 7-year time period and that the mean albuterol use decreased over that same time period. The regression analysis adjusting for differences in groups showed that a 10% increase in percentage of ICS/LABA to total ICS use ratio in the measurement year was associated with a 9% increased likelihood of the mAMR being ≥ 0.5. An incremental effect was Likelihood of Achieving an mAMR ≥ 0.5 for Each 10% Increase in Use of ICS/LABA also observed: As the ICS/LABA to total ICS use ratio increased incrementally, so did the likelihood of achieving an mAMR of ≥ 0.5. This suggests that an increase in percentage of ICS/LABA used may be associated with lower asthma exacerbation risk in a population of asthma patients.
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